The study visits are those routinely performed in the standard care of the subjects using PEP and are the following:~Visit 1 (between day 1 to day 8 after PEP treatment initiation):~Subject information and inclusion in the study,~Pregnancy test (urine or serum) for women of childbearing potential (WOCBP)~Delivery of a follow-up subject diary (daily information about PEP treatment intake, concomitant treatments and potential side effects/adverse events)~Visit 2 (From 42 days to 90 days after PEP treatment initiation)~Treatment observance (PEP),~Return of the follow-up subject diary,~Check of the follow-up subject diary completion,~Keep a copy of the HIV serology and/or viral load results in the medical file.
The main objective of this observational study is to assess the adherence of post exposure prophylaxis treatment with doravirine (using Delstrigo® or Pifeltro®), prescribed to subjects exposed to HIV according to French national recommendations.~This study will evaluate:~the percentage of subjects who followed their treatment within the prescribed 28 days,~the prevalence and type of side effects in subjects on this treatment,~the occurrence of HIV seroconversion associated with this combination.